Inari Medical Expands Treatment Options

Inari Medical Inc. (Nasdaq: NARI) announced late last month its FlowTriever system received federal clearance to treat right atrium clot in transit (CIT). 

It is the only approved clot-removal device for the life-threatening condition, which involves a free-floating clot in the right side of the heart and is usually associated with pulmonary embolism (PE). 

About 200,000 patients suffer from PE every year, and patients with acute PE are estimated to have a mortality rate as high as 30%. 

The new indication is the latest sign of Inari’s efforts to expand treatment options for patients with clotting disorders; its two main devices, the FlowTriever and ClotTriever, cost an average of $9,100 per procedure, according to regulatory filings.

Analysts are projecting sales will more than double to $129.8 million in 2020 and climb another 35% in 2021 to $176 million. In 2018, its first year of sales, it reported $6.8 million.

Inari has seen its stock price increase fourfold since its initial public offering in May, with shares rising from $19 to almost $87 at press time. 

The fast-grower now sports a nearly $4.3 billion market capitalization, up from $3.2 billion at the beginning of December.